Slide 1: We want to save patients with severe cancer and autoimmune diseases
We want to save patients with severe cancer and autoimmune diseases Clinical investigations with our lead antibody CAN04 to our proprietary target Göran Forsberg, CEO March 2021
Slide 2: Safe Harbour Statement
Safe Harbour Statement Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known an
Slide 3: I. Introduction
I. INTRODUCTION
Slide 4: Cantargia – Opportunity to save lives and create value
Cantargia – Opportunity to save lives and create value Discovery Preclinical Project phase phase Phase I Phase II Phase III Commercial phase CAN04 ➢ Potentially more effective treatment against novel Pancreatic cancer Chemo combinations target in clinically validated Non-small cell lung cancer Chemo
Slide 5: Cantargia highlights
Cantargia highlights UNIQUE IMMUNOTHERAPY ANTIBODY CAN04 IN PHASE IIA CLINICAL DEVELOPMENT • Positive interim data set - response rates higher than historical control Current owners (30 Dec 2020) • First in class antibody with broader MOA than competitors PLATFORM WITH MANY POTENTIAL THERAPEUTIC ARE
Slide 6: II. Lead antibody CAN04
II. LEAD ANTIBODY CAN04
Slide 7: Cantargia addresses NSCLC & PDAC
Cantargia addresses NSCLC & PDAC 12% Lung Non-Small Cell Lung Cancer Pancreatic cancer Breast 12% Bowel Prostate 43% Stomach Incidence Liver 10% Larynx Cervix 2.1m Annual global incidences 0.5m Annual global incidences 7% Other 3% 3% 5% 6% 12% Fraction of cancer incidence 3% Fraction of cancer incid
Slide 8: Inflammatory IL-1 pathway validated as target
Inflammatory IL-1 pathway validated as target Cantos trial (n=10,061) Canakinumab phase III trials • Canakinumab (Novartis) ADJUVANT NSCLC • 1,500 patients (recruiting) • Reduced lung cancer incidence by 67% and death by 77% (CANOPY-A) • After surgery, no mets, placebo control • Reduced non-lung can
Slide 9: CAN04 – Dual anticancer mechanism
CAN04 – Dual anticancer mechanism NSCLC IL1a IL1b Inhibition of IL-1 signaling ADCC enhanced antibody Ctrl CAN04 BLOCKS BOTH FORMS OF IL-1 AND STIMULATES DIRECT KILLING OF CANCER CELLS 9
Slide 10: CAN04 – Differentiated and superior MOA
CAN04 – Differentiated and superior MOA Cancer context IL-1α IL-1β comment Localization • Cellbound and soluble • Soluble • IL-1α trigger and IL-1β • Cancer cells and stroma enhance inflammation • Often work in pair Function • Stimulates inflammation - IL1R1 -forming complex with IL1RAP • No known d
Slide 11: CAN04 – Mechanism of action
CAN04 – Mechanism of action ADCC – Reduced activation Reduced Tumor cell death and infiltration of angiogenesis immunosuppressive cells CAN04 BLOCKS BOTH FORMS OF IL-1 AND CAN ERADICATE CELLS MEDIATING THE EFFECTS OF IL-1 Note: ADCC = Antibody-Dependent Cellular Cytotoxicity. CAF = Cancer-Associated
Slide 12: Targeting IL1RAP allows unique synergistic effects with chemotherapy (AACR 2020)
Targeting IL1RAP allows unique synergistic effects with chemotherapy (AACR 2020) → Upregulation of both forms of IL-1 in PDX-model as response to Gem/Cis → IL-1α (DAMP) on cancer cells trigger inflammasome activation in tumor microenvironment (e.g. IL-1β) → CAN04 increases efficacy of Pt based chemo
Slide 13: Tumor shrinkage – NSCLC combination
Tumor shrinkage – NSCLC combination → CAN04 in combination with gem/cis in 1st line chemotherapy Patient → 6 of 9 evaluable patients with metastatic non-small cell lung 1 2 3 4 5 6 7 8 9 0 cancer (NSCLC) showed objective response including 1 Percent tumor reduction complete response (67% vs historic
Slide 14: Positive interim data – pancreatic cancer
Positive interim data– pancreatic cancer RECIST 1.1 Patient X CA19-9 Patient X 50 500 RECIST 1.1 (mm) 40 400 CA19-9 (kE/L) 30 300 20 200 10 100 0 0 0 10 20 30 0 10 20 30 Visit Visit RECIST 1.1 Patient Y CA19-9 Patient Y 40 150 RECIST 1.1 (mm) 30 CA19-9 (kE/L) 100 20 50 10 0 0 0 10 20 30 → CAN04 comb
Slide 15: IL1RAP in several cancer with high medical need
IL1RAP in several cancer with high medical need IL1RAP % of patients with IL1RAP CANTARGIA • Discovery of IL1RAP on cancer cells Cancer cell surface Stroma FOUNDATION • Antibodies against IL1RAP – antitumor effects 100 • IP on antibody therapy against IL1RAP 90 80 PRIMARY • Non-small cell lung cance
Slide 16: US Phase I clinical trial
US Phase I clinical trial → First patient started → Combination with checkpoint inhibitor in patients no longer responding to PD1/PDL-1 therapy → Primary endpoint safety, secondary endpoints include biomarkers and efficacy → Indications include NSCLC, HNSCC, malignant melanoma and bladder cancer (18
Slide 17: CAN04 – Broadening development
CAN04– Broadening development DISCOVERY PRECLINICAL COMMERCIAL PROJECT PHASE PHASE PHASE I PHASE II PHASE III PHASE CAN04 Pancreatic cancer Chemo combinations CAN04 gem/nab-paclitaxel extension ongoing CAN04 FOLFIRINOX combination submitted (France, Spain) Non-small cell lung Chemo combinations Recr
Slide 18: III. Untapped possibilities in autoimmune diseases
III. UNTAPPED POSSIBILITIES IN AUTOIMMUNE DISEASES
Slide 19: CAN10 – New development project
CAN10 – New development project → IL1RAP binding antibody potently blocking IL-1, IL-33 and IL-36 → Unique anti-inflammatory activity observed in mouse model → Development focusing on unmet medical need in systemic sclerosis and myocarditis. Disease selection in collaboration with experts based on s
Slide 20: CAN10 counteract inflammation in disease model
CAN10 counteract inflammation in disease model Total back score Isotype anti-IL-1β mCAN10 Dexamethasone → Mechanistic proof of concept for IL1RAP blockade in inflammatory driven psoriasis model 5 → Effect not dependent on IL-1β blockade 4 3 Score (0-8) 2 1 0 0 1 2 3 4 5 6 7 Days CAN10 HAS UNIQUE ANT
Slide 21: IV. Milestones and summary
IV. MILESTONES AND SUMMARY
Slide 22: Cantargia has several near-term value inflection points
Cantargia has several near-term value inflection points Newsflow over next 6–9 months CAN04 → New results PDAC, NSCLC and Keytruda combination → Next steps combination therapy PDAC and NSCLC → Phase IIa biomarker/biopsy results → Start new clinical trials • FOLFIRINOX combination PDAC • Basket trial
Slide 23: Cantargia highlights
Cantargia highlights UNIQUE IMMUNOTHERAPY ANTIBODY CAN04 IN PHASE IIA CLINICAL DEVELOPMENT • First in class antibody with broader MOA than competitors • Positive interim data set and further phase II milestones during 2021 PLATFORM WITH MANY POTENTIAL THERAPEUTIC AREAS • Cancer and large number of a